Troy Curnutt is a transformative entrepreneur in the nuclear medicine field, spearheading innovation through his companies, Advanced Molecular Compounding (AMC) and ARDDS. With a passion for improving patient care and extensive experience, Troy is revolutionizing the industry with groundbreaking solutions like AMC’s mobile nuclear pharmacy and ARDDS’ dose-drawing robot, leading the way in advancing radiopharmacy technology.

Doug Cluff is the Lead R&D Manager at Advanced Molecular Compounding (AMC) and a trailblazer in the development of innovative technology solutions. With over 15 years of experience in designing cutting-edge systems, Doug brings unmatched expertise and leadership to AMC’s mission of revolutionizing nuclear medicine. His forward-thinking approach and dedication to excellence have played a critical role in advancing AMC’s mobile nuclear pharmacy solutions, earning him the respect of his peers and clients. Doug’s contributions are invaluable to AMC’s continued success, and we are proud to have him on our team.

With extensive experience in the pharmaceutical industry, Justin Curnutt is a trusted leader in nuclear medicine compounding, quality control, and regulatory compliance at Advanced Molecular Compounding (AMC). His dedication to patient safety and his passion for using innovative technology to streamline processes have been instrumental in AMC’s success. Justin’s expertise and forward-thinking approach continue to push the boundaries of what’s possible in nuclear pharmacy, ensuring AMC remains at the forefront of the industry.